Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
Date:3/19/2013

erially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen Announces 2013 Second Quarter Dividend
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
5. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
7. Amgen Announces 2012 Third Quarter Dividend
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen to Acquire Micromet
10. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
11. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... COLLEGE PARK, Md., Dec. 23, 2010 Martek Biosciences, ... Institute (Mtech) at the University of Maryland, entered an ... Dutch company Royal DSM NV for $1.1 billion, the ... Martek is the second company sold ...
... Pathfinder LLC, a private biotechnology company focused on ... ("Pathfinder"), and SyntheMed, Inc. (OTC Bulletin Board: ... today announced that they have entered into a definitive ... Cell Therapy, Inc." and the combined company will operate ...
... University of Santiago de Compostela (USC) have analysed levels of ... Galicia. The results show that 34% of these schools exceed ... Excessive inhalation of radon is associated with lung cancer. ... 34% had radon levels in excess of 400 Bequerels/m3 in ...
Cached Biology Technology:Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 3Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 2Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 3Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 5Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 634 percent of Galician secondary schools exceed maximum recommended radon levels 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... developed from plant biomass and purpose-grown crops can substantially ... report says, but only through the wise allocation of ... the state. That,s the conclusion of "California Energy ... California Council on Science and Technology (CCST) co-authored by ...
... proposed an answer to the long-running debate as to how ... core-driven magnetic field, oceans of liquid water, dynamic climate and ... known Universe. Life arose on Earth over three and a ... planetary scale calamities such as the impacts of massive meteorites, ...
... Methanosarcina acetivorans lives off everything it can metabolize ... is not yet clear. Scientists at the Ruhr-Universitt Bochum ... USA have identified a protein that might act as ... and found both similarities and differences to the system ...
Cached Biology News:Biofuels will play integral role in California's energy future, says new EBI study 2Biofuels will play integral role in California's energy future, says new EBI study 3New study proposes solution to long-running debate as to how stable the Earth system is 2How Archaea might find their food 2
... is produced by a patented microwave process ... more consistent, even cell attachment, increased cell ... and growth uunder difficult conditions, including reduced ... provide a more ecominic alternative to expensive ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Biology Products: